The latest: Biopharmaceutical company Antengene Corp. Ltd. (6996.HK) said on Wednesday it has agreed to acquire the remaining interest it doesn’t already hold in the anti-tumor drug ATG-037 from Calithera Biosciences (CALA.US), giving it ownership of all related patent materials.

Looking up: While no terms of the agreement were disclosed, Antengene will no longer need to make any future milestone or royalty payments to Calithera.

Take Note: Exclusive ownership of ATG-037 means Antengene has to bear the clinical trial, development and commercialization costs of ATG-037 alone unless it finds other development partners.

Digging Deeper: In May 2021, Antengene entered into a worldwide exclusive licensing agreement with Calithera to develop and commercialize ATG-037, including an initial upfront payment to Calithera and future milestone and royalty payments based on the drug’s development. ATG-037 is an oral inhibitor of CD73, a small molecule that triggers immunosuppression in the tumor microenvironment by interfering with the anti-tumor immune response through the production of adenosine. Its Phase 1 clinical trial application for the treatment of locally advanced and metastatic solid tumors was approved in China last November, but is expected to face a long road to commercialization.

Market Reaction: Antengene shares jumped on Thursday to close up 9.8% at HK$5.96 by the midday break. The stock now trades in the middle of its 52-week range.

Translation by Jony Ho

To subscribe to Bamboo Works free weekly newsletter, click here

Recent Articles

Noah does wealth management

Noah finds second life in overseas voyage

The wealth manager’s international businesses drove it back to revenue growth in the second quarter as challenges continued to linger at home Key Takeaways: Noah Holdings’ overseas revenue increased about…
Illustration of China solar industry

China moves to end solar bloodbath, as East Buy chases warehouse club crown

China is floating yet another plan to rescue its oversupplied solar sector, including a mass shuttering of excess capacity. Will the government-led effort work this time? And a former online educator says it wants to become the new online Sam's Club of China. Does East Buy have what it takes to succeed?